Micronized Palmitoylethanolamide-Polydatin Reduces the Painful Symptomatology in Patients with Interstitial Cystitis/Bladder Pain Syndrome
Aims. To assess the efficacy of a micronized-palmitoylethanolamide-polydatin (m-PEA-Pol) based product on chronic pelvic pain and severity of other symptoms in interstitial cystitis/bladder pain syndrome (IC/BPS) patients refractory to conventional therapies. Methods. A pilot, open-label bicentric s...
Main Authors: | M. Cervigni, L. Nasta, C. Schievano, N. Lampropoulou, E. Ostardo |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2019-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2019/9828397 |
Similar Items
-
Interstitial cystitis: painful bladder syndrome
by: R F Sholan, et al.
Published: (2018-02-01) -
Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study
by: Stochino Loi E, et al.
Published: (2019-08-01) -
'Omics' Approaches to Understanding Interstitial Cystitis/Painful Bladder Syndrome/Bladder Pain Syndrome
by: Sungyong You, et al.
Published: (2012-12-01) -
Bladder pain syndrome/interstitial cystitis is associated with hyperthyroidism.
by: Shiu-Dong Chung, et al.
Published: (2013-01-01) -
The Evaluation and Management of Interstitial Cystitis/Bladder Pain Syndrome
by: Samantha Kraemer, et al.
Published: (2019-04-01)